A pharmaceutical developer has identified a promising

antibiotic candidate with potent activity against highly drug‑resistant

bacterial pathogens. While early laboratory and animal data are encouraging,

the team anticipates significant obstacles when designing Phase III clinical

trials compared with trials for infections caused by drug‑susceptible

organisms.

Which issue most plausibly accounts for these difficulties?